Investors bought shares of Becton, Dickinson and Company (NYSE:BDX) on weakness during trading on Friday. $44.38 million flowed into the stock on the tick-up and $30.44 million flowed out of the stock on the tick-down, for a money net flow of $13.94 million into the stock. Of all equities tracked, Becton, Dickinson and had the 28th highest net in-flow for the day. Becton, Dickinson and traded down ($0.29) for the day and closed at $199.15

A number of brokerages recently weighed in on BDX. Barclays PLC restated an “equal weight” rating and set a $210.00 target price (up from $205.00) on shares of Becton, Dickinson and in a report on Thursday, August 10th. BidaskClub downgraded shares of Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Stifel Nicolaus restated a “buy” rating on shares of Becton, Dickinson and in a report on Wednesday, August 9th. Zacks Investment Research downgraded shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a report on Monday, August 7th. Finally, Cowen and Company restated an “outperform” rating and set a $230.00 target price (up from $200.00) on shares of Becton, Dickinson and in a report on Monday, July 10th. One analyst has rated the stock with a sell rating, five have issued a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. Becton, Dickinson and presently has a consensus rating of “Buy” and a consensus price target of $195.79.

The firm has a market capitalization of $45.32 billion, a P/E ratio of 57.67 and a beta of 1.06. The stock’s 50 day moving average price is $200.24 and its 200 day moving average price is $190.15.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, topping the consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The company had revenue of $3.04 billion during the quarter, compared to analyst estimates of $3.06 billion. During the same quarter last year, the firm posted $2.35 EPS. The firm’s revenue for the quarter was down 5.1% on a year-over-year basis. Equities analysts forecast that Becton, Dickinson and Company will post $9.46 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be issued a $0.73 dividend. This represents a $2.92 annualized dividend and a yield of 1.47%. The ex-dividend date is Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio (DPR) is currently 83.43%.

In other Becton, Dickinson and news, EVP Linda M. Tharby sold 4,695 shares of the firm’s stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $200.48, for a total value of $941,253.60. Following the completion of the transaction, the executive vice president now owns 18,670 shares in the company, valued at approximately $3,742,961.60. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Ribo Alberto Mas sold 7,463 shares of the firm’s stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $201.41, for a total value of $1,503,122.83. Following the completion of the transaction, the executive vice president now owns 29,323 shares of the company’s stock, valued at approximately $5,905,945.43. The disclosure for this sale can be found here. In the last three months, insiders sold 48,605 shares of company stock valued at $9,718,986. 1.40% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Becton, Dickinson and by 8.5% in the second quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock valued at $3,366,809,000 after buying an additional 1,353,780 shares in the last quarter. BlackRock Inc. increased its position in shares of Becton, Dickinson and by 2,427.8% in the first quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock valued at $3,034,470,000 after buying an additional 15,887,611 shares in the last quarter. State Street Corp increased its position in shares of Becton, Dickinson and by 3.5% in the second quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock valued at $2,003,834,000 after buying an additional 342,873 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Becton, Dickinson and by 6.5% in the first quarter. JPMorgan Chase & Co. now owns 3,967,843 shares of the medical instruments supplier’s stock valued at $727,863,000 after buying an additional 242,081 shares in the last quarter. Finally, Wells Fargo & Company MN increased its position in shares of Becton, Dickinson and by 1.2% in the first quarter. Wells Fargo & Company MN now owns 3,283,068 shares of the medical instruments supplier’s stock valued at $602,246,000 after buying an additional 39,362 shares in the last quarter. Institutional investors and hedge funds own 87.41% of the company’s stock.

WARNING: This report was published by Daily Political and is owned by of Daily Political. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.dailypolitical.com/2017/09/03/investors-buy-shares-of-becton-dickinson-and-company-bdx-on-weakness-2.html.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.